Express Mail Label No.: EL 985 780 159 US

Date of Deposit: 10 28/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application	on of SCARLATO et al.		
Serial No.:	CON of 09/302,626	Examiner:	Unassigned
Confirmation ?	No.:	Art Unit:	Unassigned
Filed:	On even date herewith		
For:	MENINGOCOCCAL ANTIGENS		

Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

7 and 1	.98.
[]	Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.
[X]	No copies of the publications listed on the attached Form PTO/SB/08A are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. 09/302,626 to which the above-identified application claims priority under 35 U.S.C. §120.
[]	Publication(s) listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to application serial no and mailed on
[]	Enclosed is a copy of a non-English publication(s) Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).

Page 2	2
--------	---

[]	Enclosed is a copy of a non-English publication(s) English language
	publication (copy enclosed) claims priority from this non-English
	publication.

- [] Enclosed is an explanation of non-English publication(s) ___ for which an English translation is not available.
- [] Enclosed is an English translation of non-English publication(s) __cited in the attached Form PTO/SB/08A.
- [] Enclosed is a copy of pending patent Application Serial No. ___.

This Information Disclosure Statement is filed with the herein continuation application.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Please direct all further written communications in this application to:

Alisa A. Harbin Chiron Corporation Intellectual Property – R440 P.O. Box 8097 Emeryville, CA 94662-8097.

Dated: 10/28/63

Respectfully submitted,

Chiron Corporation Intellectual Property – R440 P.O. Box 8097 Emeryville, CA 94662-8097

Tel: (650) 493-3400 Fax: (650) 493-3440 By:

Roberta L. Robins Reg. No. 33,208

Sub	stitute for form 14	49A/PT()		Complete if Known	
				Application Number	CON of 09/302,626	
IN	FORMATIO	ON DI	SCLOSURE	Filing Date	On even date herewith	
SI	TATEMENT	BY A	PPLICANT	First Named Inventor	SCARLATO	
				Group Art Unit	Unassigned	
	(use as many s	heets as	necessary)	Examiner Name	Unassigned	
Sheet	1	of	3	Attorney Docket Number	2300-0363 (PP00363.115)	

-	U.S. PATENT DOCUMENTS							
		U.S. Patent Document			Data of D. I. Vissalina of City of			
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	Al	6,197,312		Peak et al.	03-06-2001			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite Foreign Patent Document		Name of Patentee or Applicant of Cited	Date of Publication				
initials 140.	Office	Number ⁴	Kind Code ⁵ (if known)	Document Document	of Cited Document MM-DD-YYYY	T ⁶		
	Bl	EP	0 467 714	A1	Merck & Co., Inc.	01-22-1992		
_	B2	wo	95/03413	Al	The Rockefeller University et al.	02-02-1995		
	B3	wo	96/29412	A1	IAF Bio Vac Inc.	09-26-1996		
	B4	WO	95/33049	A2	Pasteur Merieux Serums et Vaccins Transgene S.A.	12-07-1995		
	B5	WO	96/30519	A1	Washington University	10-03-1996		

Examiner	 Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

		100 000			Complete if Known	
Substit	tute for form 144	19B/P1C)	Application Number	CON of 09/302,626	
TAIR			OOL OOLDD	Filing Date	On even date herewith	
INFORMATION DISCLOSURE				First Named Inventor	SCARLATO	
STA	TEMENT	BY A	PPLICANT	Group Art Unit	Unassigned	
(1	use as many sl	heets as	necessary)	Examiner Name	Unassigned	
Sheet	2	of	3	Attorney Docket Number	2300-0363 (PP00363.115)	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Examiner initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	C1	ALDEEN et al., "The meningococcal transferring-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains," Vaccine 14(1):49-53, 1996					
3	C2	CONSTANTINO et al., "Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C," Vaccine 10:691-698					
	C3	JAFARI et al., "Control and prevention of meningococcal disease: recommendations of the advisory committee on immunization practices (ACIP)," MMWR 46(RR-5):1-10, 1997					
	C4	LIEBERMAN et al., "Safety and immunogenicity of a serogrooups A/C Neisseria meningitides oligosaccharide-protein conjugate vaccine in young children," JAMA 275(19):1499-1503, 1996					
,	C5	PERKINS et al., "Control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations for the advisory committee on immunization practices (ACIP)," MMWR 46(RR-5):13-21, 1997					
	C6	POOLMAN, "Development of a mengococcal vaccine," Infections agents and Disease 4:13-28, 1995					
	C7	ROKBI et al., "Evaluation of recombinant transferring-binding protein B variants from Neisseria meningitides for their ability to induce cross-reactive and bactericidal antibodies against agenetically diverse collection of serogroup B strains," Infection and Immunity 65(1):55-63, 1997					
	C8	ROKBI et al., "Heterogeneity of tbpB, the transferring-binding protein B gene, among serogroup B Neisseria meningitides strains of the ET-5 complex," Clinical and Diagnostic Lab. Immun. 4(5):522-529, 1997					
	C9	ROMERO et al., "Current status of meningococcal group B vaccine candidates: capsular or noncapsular?" Clinical Microbio. Reviews 7(4):559-575, 1994					
	C10	SCHUCHAT et al., "Bacterial meningitis in the United States in 1995," New England J. of Medicine 337(14):970-976, 1997					
	C11	WEDEGE et al., "Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting," <i>Infection and Immunity</i> 51(2):571-578, 1986					

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number.
 Applicant is to place a check mark here if English language Translation attached.

	0.1 C . C			Complete if Known	
Substitu	te for form 1449B/P7	Ю	Application Number	CON of 09/302,626	
			Filing Date	On even date herewith	
INFO	RMATION D	ISCLOSURE	First Named Inventor	SCARLATO	
STAT	TEMENT BY	APPLICANT	Group Art Unit	Unassigned	
(us	se as many sheets o	as necessary)	Examiner Name	Unassigned	
Sheet	3 of	3	Attorney Docket Number	2300-0363 (PP00363 115)	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country	T ²			
	C12	where published. ZOLLINGER, "New and improved vaccines against meningococcal disease," in New Generation Vaccines, 2 nd Ed., pp.469-488, 1997				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number.
 Applicant is to place a check mark here if English language Translation attached.